Targeting KRAS in Colorectal Cancer

Clinical Pearls

Charles S. Fuchs, MD, MPH, director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, discusses targetingKRASin colorectal cancer.

• KRASis mutated in 40% of patients and defines who should get cetuximab or panitumumab
• Patients should be genotyped for all mutations inKRASandNRAS
• Defining drug targets against mutantKRAShas been impossible thus far